Pricing Log in Create free account
Saturday 17 October 2026 Export RVTY’s income statement to Excel — free account

Revvity Inc.

RVTY Healthcare Diagnostics & Research

Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024. In the quarter to June 2026, revenue grew 1.31%, EPS grew 2.17%, free cash flow grew 59.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

152.64 2.07 −1.34%
Market cap
$17.3B
P/E
72.7×
Fwd P/E
37.5×
Dividend yield
0.23%
F-score
6/9
Altman Z
2.49
Beneish M
−2.45
Dividend safety
80/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Revvity Inc. 10-Q filed Aug 11, 2026

Fiscal Q2 2026 · Period ended Jul 5, 2026 · Filed · accepted 4:06 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 12, 2026: 8 added · 1 removed · 26 modified; 4 with only figures updated

  1. Modified · Overview

    •Diagnostics. Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the areas of reproductive health, immunodiagnostics and emerging market diagnostics.

34 more changes in this Item, word by word, in Powerpack.

Powerpack